报价延迟最少15分钟:2026/01/05 08:34 EST
盘前时段
|
||||
|
1.02 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.02
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.12/-0.89
|
|
企业价值
150.13M
|
| 资产负债 |
|
每股账面净值
2.54
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
2.82M
|
|
每股收益
0.29
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. |
